Package Leaflet: Information for the Patient
Memantina ratiopharm 20mg film-coated tablets EFG
Memantine hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
How it worksMemantina ratiopharm
Memantina ratiopharm belongs to a group of medicines called anti-dementia medicines.
Memory loss in Alzheimer's disease is due to an alteration in brain signals. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that are involved in the transmission of important nerve signals in learning and memory. Memantina ratiopharm belongs to a group of medicines called NMDA receptor antagonists. Memantina ratiopharm acts on these receptors, improving the transmission of nerve signals and memory.
What it is used forMemantina ratiopharm
Memantina ratiopharm is used in the treatment of patients with moderate to severe Alzheimer's disease.
Do not takeMemantina ratiopharm:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Memantina ratiopharm:
In these situations, treatment should be carefully supervised and your doctor should regularly re-evaluate the clinical benefit of Memantina ratiopharm.
If you have kidney problems, your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.
The use of memantine should be avoided with other medicines such as
Children and adolescents
Memantina ratiopharm is not recommended for use in children and adolescents under 18 years of age.
Other medicines and Memantina ratiopharm
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, the administration of Memantina ratiopharm may produce changes in the effects of the following medicines, so your doctor may need to adjust the dose:
If you are admitted to hospital, inform your doctor that you are taking Memantina ratiopharm.
Taking Memantina ratiopharm with food and drinks
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from a normal diet to a strict vegetarian diet) or if you have renal tubular acidosis (RTA, excess of acid-producing substances in the blood due to kidney dysfunction) or severe urinary tract infections (urinary tract), as your doctor may need to adjust the dose of the medicine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Memantine is not recommended for use in pregnant women.
Women taking Memantina ratiopharm should stop breastfeeding.
Driving and using machines
Your doctor will inform you whether your illness allows you to drive and use machines safely.
Also, Memantina ratiopharm may alter your reaction ability, so driving or operating machinery may be inappropriate.
Memantina ratiopharm contains lactose and soy lecithin
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
This medicine contains soy lecithin. If you are allergic to peanuts or soy, do not take this medicine.
Follow exactly the administration instructions of this medicine indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Dosage
The recommended dose of Memantina ratiopharm for adults and the elderly is 20 mg once a day.
To reduce the risk of adverse effects, this dose should be achieved gradually following a daily treatment scheme. To adjust the dose, there are tablets with different doses.
At the start of treatment, you will take 5 mg once a day. This dose will be increased weekly by 5 mg until the recommended dose (maintenance dose) is reached. The recommended maintenance dose is 20 mg once a day, which is reached at the beginning of the fourth week.
The tablet can be divided into equal doses.
Dosage for patients with renal insufficiency
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should periodically monitor your kidney function.
Administration
Memantina ratiopharm should be administered orally once a day. To get the most out of your medication, you should take it every day and at the same time.
The tablets should be swallowed with a little water. The tablets can be taken with or without food.
Duration of treatment
Continue taking Memantina ratiopharm as long as it is beneficial for you. Your doctor should evaluate the effects of your treatment periodically.
If you take more Memantina ratiopharm than you should
If you forget to take Memantina ratiopharm
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Memantina ratiopharm can cause side effects, although not everybody gets them.
Generally, side effects are mild to moderate.
Frequent (affects 1 to 10in every 100patients):
Uncommon (affects 1 to 10in every 1,000patients):
Rare (affects less than 1in every 10,000patients):
Frequency not known (frequency cannot be estimated from the available data):
Alzheimer's disease has been associated with depression, suicidal ideation, and suicide. These events have been reported in patients treated with memantine.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister pack after EXP. The expiry date is the last day of the month shown.
Blister packs
Do not store above 25°C.
HDPE bottles
This medicine does not require any special storage conditions.
Shelf-life after first opening of the container: 6 months
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.
Composition of Memantina ratiopharm
Each tablet contains 20 mg of memantine hydrochloride, equivalent to 16.62 mg of memantine.
Core of the tablet
Microcrystalline cellulose (E 460), pregelatinized starch (E 1404), anhydrous lactose, colloidal anhydrous silica (E 551), magnesium stearate (E 470b).
Coating
Polysorbate 80 (E 433), polyvinyl alcohol (E 1203), titanium dioxide (E 171), talc (E 553b), soy lecithin (E 322), xanthan gum (E 415).
Appearance of the product and pack contents
White to off-white, biconvex, capsule-shaped tablets (15.6 x 8.0 mm), with a break line on one side and with the number "20" embossed on the other side.
Memantina ratiopharm is available in packs of 10, 14, 21, 28, 30, 42, 56, 98, and 100 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
ratiopharm GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany
Manufacturer
Merckle GmbH
Ludwig-Merckle-Straße 3
89143 Blaubeuren
Germany
TEVA Pharmaceutical Works Private Limited Company
Pallagi út 13, 4042 Debrecen
Hungary
HBM Pharma s.r.o.
Slabinská 30, 03680 Martin
Slovakia
You can request more information about this medicine from the local representative of the marketing authorisation holder:
Belgium Teva Pharma Belgium N.V./S.A./AG Tel: +32 3 820 73 73 | Lithuania UAB “Sicor Biotech” Tel: +370 5 266 0203 |
Bulgaria ???? ????????????? ???????? ???? Tel: +359 2 489 95 82 | Luxembourg ratiopharm GmbH Germany Tel: +49 731 402 02 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251 007 111 | Hungary Teva Gyógyszergyár Zrt. Tel: +36 1 288 64 00 |
Denmark Teva Denmark A/S Tel: +45 44 98 55 11 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +353 51 321 740 |
Germany ratiopharm GmbH Tel: +49 731 402 02 | Netherlands Teva Nederland B.V. Tel: +31 800 0228 400 |
Estonia UAB “Sicor Biotech” Eesti filiaal Tel: +372 661 0801 | Norway ratiopharm AS Tel: +47 66 77 55 90 |
Greece Teva Ελλάς Α.Ε. Tel: +30 210 72 79 099 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 007 0 |
Spain ratiopharm España, S.A. Tel: +34 91 567 29 70 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 22 345 93 00 |
France Teva Santé Tel: +33 1 55 91 78 00 | Portugal ratiopharm, Comércio e Indústria de Produtos Farmacêuticos, Lda Tel: +351 21 476 75 50 |
Croatia Pliva Hrvatska d.o.o Tel: +385 1 37 20 000 | Romania Teva Pharmaceuticals S.R.L Tel: +40 21 230 65 24 |
Ireland Teva Pharmaceuticals Ireland Tel: +353 51 321740 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 1 58 90 390 |
Iceland Medical ehf. Tel: +354 534 3500 | Slovakia TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 2 57 26 79 11 |
Italy Teva Italia S.r.l. Tel: +39 02 89 17 98 1 | Finland ratiopharm Oy Tel: +358 20 180 5900 |
Cyprus Teva Ελλάς Α.Ε., Greece Tel: +30 210 72 79 099 | Sweden Teva Sweden AB Tel: +46 42 12 11 00 |
Latvia UAB “Sicor Biotech” filiale Latvija Tel: +371 673 23 666 | United Kingdom Teva UK Limited Tel: +44 1977 628500 |
Date of last revision of this leaflet:<{MM/AAAA}><{month AAAA}>
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.